Small Intestinal Bacterial Overgrowth in Rosacea: Clinical Effectiveness of Its Eradication Andrea Parodi, Stefania Paolino, Alfredo Greco, Francesco Drago, Carlo Mansi, Alfredo Rebora, Aurora Parodi, Vincenzo Savarino Clinical Gastroenterology and Hepatology Volume 6, Issue 7, Pages 759-764 (July 2008) DOI: 10.1016/j.cgh.2008.02.054 Copyright © 2008 AGA Institute Terms and Conditions
Figure 1 Cutaneous lesions of some patients with SIBO before and after treatment with rifaximin. All patients had complete resolution of cutaneous lesions after normalization of BTs. Clinical Gastroenterology and Hepatology 2008 6, 759-764DOI: (10.1016/j.cgh.2008.02.054) Copyright © 2008 AGA Institute Terms and Conditions
Figure 2 Clinical outcome in SIBO-positive patients treated with rifaximin (eradicated patients) or placebo. Clinical Gastroenterology and Hepatology 2008 6, 759-764DOI: (10.1016/j.cgh.2008.02.054) Copyright © 2008 AGA Institute Terms and Conditions
Figure 3 Clinical outcome in SIBO-positive and SIBO-negative patients treated with rifaximin. Clinical Gastroenterology and Hepatology 2008 6, 759-764DOI: (10.1016/j.cgh.2008.02.054) Copyright © 2008 AGA Institute Terms and Conditions